Pfizer, the world’s biggest drugmaker, will pay closely held Bind Therapeutics Inc. as much as $200 million per potential drug to develop medicines using its nanotechnology platform. Bind’s technology comes from the laboratories of Robert Langer of MIT and HMS senior lecturer on surgery at Boston Children’s Hospital, and Omid Farokhzad, HMS associate professor of anaesthesia at Brigham and Women's Hospital.
News & Research
